The UK charity LifeArc has decided to sell a portion of its royalty interest in Keytruda (pembrolizumab), the hugely successful anti-PD-1 cancer therapy it co-developed with Merck & Co. Inc. It will use the funds to expand its capacity as a translational ‘bridge’ between research-oriented academia and the wider pharma industry, the UK charity’s CEO told Scrip.
Melanie Lee was speaking after LifeArc announced on 20 May that it had received just under $1.3bn from CPPIB Credit...








